| |
|
|
|
Trillium Therapeutics Inc.  
|
|
17.29 -0.01 (-0%) |
09-21 16:00 |
|
Open: |
17.3 |
Pre close: |
17.3 |
Target:
|
20.74
|
|
High: |
17.33 |
Low: |
17.25 |
Resistance:
|
17.76
20.74
|
|
Volume: |
1,400,090 |
Market Cap: |
1819M |
Support:
|
10.37
5.80
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
17.33
 |
MACD |
MACD(12,26):
|
1.75 |
|
MA(20): |
17.33 |
Signal(12,26,9): |
2.09 |
|
MA(100): |
10.19  |
Stochastic Oscillator |
%K(14,3):
|
70.18 |
|
MA(250): |
11.85 |
%D(3): |
70.47 |
|
Average Volume(K) |
3-Month: |
20801540
|
52-Week |
High:
|
20.96 |
|
10-Days: |
191180 |
Low: |
5.80 |
|
RSI |
RSI(14):
|
80.26 |
Change(%): |
24.0 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.570 |
Return on Equity (ttm) |
-30.2 |
Shares Out. (M) |
103.14 |
|
EPS Est. Current Year |
-4.130 |
Return on Assets (ttm) |
-16.4 |
Shares Float (M) |
86.41 |
|
EPS Est. Next Year |
-2.740 |
PEG Ratio |
0.00 |
% Held by Insiders |
6.39 |
|
EPS Est. Next Quarter |
-0.960 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
76.09 |
|
Forward EPS |
-3.621 |
Gross Profit (p.s.) |
0.001 |
Shares Short (K) |
9890 |
|
Book Value (p.s.) |
2.500 |
EBITDA (p.s.) |
-0.539 |
P/E |
-30.33 |
|
Sales Per Share |
0.001 |
Qtrly Earnings Growth |
0.00 |
P/BV |
6.92 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-32.52 |
P/S |
12049.26 |
|
Operating Margin |
-37909.46 |
Levered Free Cash Flow
(M) |
-21.88 |
P/CF |
-54.84 |
|
|
|
|
|
|
